ANXA11 and hepatocellular carcinoma: In conclusion, we demonstrated that AGAP2-AS1 was up-regulated in HCC, and could promote cell proliferation, migration, invasion, EMT progression and inhibited apoptosis of HCC cells via AGAP2-AS1/miR-16-5p/ANXA11/AKT axis, which could be a valuable and promising therapeutic target for HCC.